

8:45 Welcome
Moderation: A. Heidenreich, Cologne, GER

08:50 Prostate Cancer: early detection, screening and diagnosis
Moderation: A. Heidenreich, Cologne, GER | M. Schostak, Berlin, GER

08:50 Individualized early detection: PROBAST
R. Al-Monajjed, Düsseldorf, GER

09:03 Prostate cancer screening with PSA, kallikrein panel and MRI: the ProScreen trial
A. Auvinen, Tampere, FIN

09:16 Hot Topic: Optimum
M. Schostak, Berlin, GER

09:42 Urothelial carcinoma 1: non-muscle invasive deintensification of follow-up and active treatment
F. Roghmann, Herne, GER | F. Schmid, Cologne, GER

09:42 Case Presentation: pTa, low grade
L. Bohn, Cologne, GER

09:44 TUR-B remains standard management
R. Schiavina, Bologna, IT

09:54 Active Surveillance ± outpatient fulguration
M. Babjuk, Prague, CZ

10:04 Role of urinary markers
T. Ecke, Bad Saarow, GER

10:14 Discussion

10:24 Treatment strategies for BCG-refractory TCC: Pro and Contra

10:24 Case presentation
O. Steenbook, Cologne, GER

10:26 Radical cystectomy remains as best option
S. Roghmann, Herne, GER

10:36 Intravesical salvage is an an good option
M. Babjuk, Prag, CZ

10:46 Discussion

10:50 Coffee Break

11:25 PCA – intermediate risk favourable: what to do?
Moderation: A. Blana, Fürth, GER | A. Auvinen, Tampere, FIN

11:25 Case Presentation
R. Weiten, Cologne, GER

11:27 Active Surveillance
M. Schostak, Berlin, GER

11:37 nsRLAP
J. Karnes, Rochester, USA

11:47 Extreme hypofractionation: the gold standard in modern radiotherapy?
E. Fokas, Cologne, GER

11:57 HIFU
A. Blana, Fürth, GER

12:07 Discussion

12:15 Satellite Symposium 1: Johnson & Johnson
Personalized, Precise, Pioneering: Innovations and Data Shaping the Future of Prostate and Bladder Cancer Therapy
A. Heidenreich, Cologne, GER | S. Zschäbitz, Heidelberg, GER

13:00 Lunch Break

13:55 Urothelial carcinoma 2: locally advanced/metastasised
F. Roghmann, Herne, GER | A. Heidenreich, Cologne, GER

13:55 Case Presentation: Urothelial carcinoma of the bladder cT3cN1cM1a, 6 cycles ddMVAC => ycT2cN0cM0
C. Rieger, Cologne, GER

13:57 It is still a palliative treatment
L. Caruscelli, Munich, GER

14:07 Cytoreductive radical cystectomy + pLAD + RPLA
S. Lerner, Houston, USA

14:17 Cytoreductive radiation therapy is the best alternative
U. Ganswindt, Innsbruck, AT

14:27 Discussion

14:35 Satellite Symposium 2: AstraZeneca GmbH
Opportunities for perioperative therapy in MIBC
S. Machtens, Bergisch-Gladbach, GER | D. Pfister, Cologne, Germany

15:20 Urothelial carcinoma 3: Urinary bladder muscle-invasive, organ-confined
Moderation: C. Rieger, Cologne, GER | H. Kübler, Würzburg, GER

15:20 Neoadjuvant therapy: which regime to take?
A. Lorch, Zurich, CH

15:35 Complete Response – cured?
S. Lerner, Houston, USA

15:50 Discussion

16:00 Coffee Break

16:35 Prostate cancer 1: low volume de novo PCA
Moderation: A. Blana, Fürth, GER | F. Schmid, Cologne, GER

16:35 Case Presentation
J. Heidenreich, Cologne, GER

16:37 System therapy does everything
S. Zschäbitz, Heidelberg, GER

16:47 Surgical eradication is also required
J. Karnes, Rochester, USA

16:57 Only radiotherapy is successful
U. Ganswindt, Innsbruck, AT

17:07 Discussion

17:15 Special Lecture
Moderation: A. Heidenreich, Cologne, GER
Correct interpretation of clinical trials for the benefit of our patients
K. Binder, Munich, GER

17:45 Semi-Live
Moderation: D. Pfister, Cologne, GER | A. Heidenreich, Cologne, GER

17:45 RPLA in germ cell tumors
A. Heidenreich, Cologne, GER

17:57 Caval thrombus in renal cell carcinoma
A. Haferkamp, Mainz, GER

18:09 Radio-guided sentinel lymphadenectomy in prostate cancer
L. Fumado, Barcelona, ESP

18:21 Discussion

18:30 End of Day 1